Research Papers:

Importance of activated leukocyte cell adhesion molecule (ALCAM) in prostate cancer progression and metastatic dissemination

Andrew J. Sanders _, Sioned Owen, Liam D. Morgan, Fiona Ruge, Ross J. Collins, Lin Ye, Malcolm D. Mason and Wen G. Jiang

PDF  |  Full Text  |  Supplementary Files  |  How to cite

Oncotarget. 2019; 10:6362-6377. https://doi.org/10.18632/oncotarget.27279

Metrics: PDF 1275 views  |   Full Text 1942 views  |   ?  


Andrew J. Sanders1, Sioned Owen1,3, Liam D. Morgan1, Fiona Ruge1, Ross J. Collins1, Lin Ye1, Malcolm D. Mason2 and Wen G. Jiang1

1 Cardiff China Medical Research Collaborative (CCMRC), Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK

2 Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK

3 Alfred Russel Wallace Building, Upper Glyntaff, University of South Wales, Pontypridd, UK

Correspondence to:

Andrew J. Sanders,email: [email protected]

Keywords: ALCAM; prostate cancer; bone; metastasis; serum biomarker

Received: May 09, 2019     Accepted: September 05, 2019     Published: October 29, 2019


Activated Leukocyte Cell Adhesion Molecule (ALCAM) has been linked to the progression of numerous human cancers, where it appears to play a complex role. The current study aims to further assess the importance of ALCAM in prostate cancer and the prognostic potential of serum ALCAM as a biomarker for prostate cancer progression. Here we demonstrate enhanced levels of tissue ALCAM are associated with metastasis. Additionally, elevated serum ALCAM is indicative of progression and poorer patient outlook, and demonstrates comparable prognostic ability to PSA in terms of metastasis and prostate cancer survival. ALCAM suppression enhanced proliferation and invasiveness in PC-3 cells and motility/migration in PC-3 and LNCaP cells. ALCAM suppressed PC-3 cells were generally less responsive to HGF and displayed reduced MET transcript expression. Furthermore a recombinant human ALCAM-Fc chimera was able to inhibit LNCaP cell attachment to HECV and hFOB1.19 cells. Taken together, ALCAM appears to be a promising biomarker for prostate cancer progression, with enhanced serum expression associated with poorer prognosis. Suppression of ALCAM appears to impact cell function and cellular responsiveness to certain micro environmental factors.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27279